Skip to content

A prospective randomized controlled trial on the effect of omentum wrapped pancreaticojejunostomy on pancreatic fistula and other complications

A prospective randomized controlled trial on the effect of omentum wrapped pancreaticojejunostomy on pancreatic fistula and other complications

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036478
Enrollment
Unknown
Registered
2020-08-23
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periampullary and pancreatic tumor

Interventions

Conventional group:mental wrapping group
Experimental group:omental wrapping of pancreaticojejunostomy

Sponsors

The Third Affiliated Hospital of the Second Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Aged under 70 years old male and female; (2) ECoG score <=2; (3) Preoperative diagnosis of periampullary tumor; (4) Preoperative imaging examination showed that radical resection of the tumor could be completed, and there was no invasion of the superior mesenteric vessels; (5) No distant lymph node metastasis such as mesenteric root was found during the operation; (6) Pancreatoduodenectomy and lymph node dissection were performed in 8,9,12,13 groups; (7) Willing to sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Intraoperative exploration revealed intrahepatic metastasis, distant organ metastasis or intraperitoneal implantation metastasis; (2) Lymph node metastasis is beyond the scope of radical resection; (3) Radical resection was performed unconditionally; (4) A large amount of ascites was found during the operation, the patient's general condition was unstable, and he could not tolerate the major operation; (5) There are any other serious diseases that the researchers believe may affect the treatment, follow-up or evaluation of the patients. It includes any uncontrolled and clinically significant heart, lung, kidney, digestive, neurological, mental illness, immune regulatory disease, metabolic disease and infectious disease; (6) Those who are unable or unwilling to provide informed consent or fail to comply with the test requirements.

Design outcomes

Primary

MeasureTime frame
amylase;

Countries

China

Contacts

Public ContactJian Liu

The Third Affiliated Hospital of the Second Military Medical University

Jianliu926@163.com+86 13918522382

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026